Actinium Pharmaceuticals, Inc.ATNMNYSE
Loading
Year-over-year earnings per share growth rate
5Y CAGR
+17.5%/yr
Long-term compound
Percentile
P72
Within normal range
vs 5Y Ago
2.2x
Strong expansion
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | 27.27% |
| Q2 2025 | 56.86% |
| Q1 2025 | -142.86% |
| Q4 2024 | 43.24% |
| Q3 2024 | 2.63% |
| Q2 2024 | -22.58% |
| Q1 2024 | 8.82% |
| Q4 2023 | 30.61% |
| Q3 2023 | 15.52% |
| Q2 2023 | -34.88% |
| Q1 2023 | -10.26% |
| Q4 2022 | -5.41% |
| Q3 2022 | -12.12% |
| Q2 2022 | -43.48% |
| Q1 2022 | 37.84% |
| Q4 2021 | -23.33% |
| Q3 2021 | -20.00% |
| Q2 2021 | 13.79% |
| Q1 2021 | 17.14% |
| Q4 2020 | 2.78% |
| Q3 2020 | 12.20% |
| Q2 2020 | 58.16% |
| Q1 2020 | -16.67% |
| Q4 2019 | 30.58% |
| Q3 2019 | -21.00% |
| Q2 2019 | 33.33% |
| Q1 2019 | 9.09% |
| Q4 2018 | 8.33% |
| Q3 2018 | -36.36% |
| Q2 2018 | 37.14% |
| Q1 2018 | -20.00% |
| Q4 2017 | 32.95% |
| Q3 2017 | 28.30% |
| Q2 2017 | 15.94% |
| Q1 2017 | -19.61% |
| Q4 2016 | 12.77% |
| Q3 2016 | 1.19% |
| Q2 2016 | -40.00% |
| Q1 2016 | 32.28% |
| Q4 2015 | -47.67% |